logo
Select company
Select metric
$ -78.44MEarnings Before Interest Taxes & Depreciation Amortization (EBITDA)
VS
Market
9
Sector
23
Industry
35
History
85
$ 5.93Close
$ 3.54 - $ 14.85 52-Week Range
Ticker Information

Ticker

KPTI

Company Name

KARYOPHARM THERAPEUTICS INC

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

KARYOPHARM THERAPEUTICS INC - Earnings Before Interest Taxes & Depreciation Amortization (EBITDA) Chart Analysis (TTM)

From
Zoom
1Y
3Y
5Y
10Y

KPTI - EBITDA Historical data
DateDepreciation, Amortization & AccretionEarning Before Interest & Taxes (EBIT)Earnings Before Interest Taxes & Depreciation Amortization (EBITDA)
6/30/2025$ 320K$ -78.76M$ -78.44M
3/31/2025$ 333K$ -19.97M$ -19.64M
12/31/2024$ 340K$ -38.94M$ -38.6M
9/30/2024$ 336K$ -54.76M$ -54.42M
6/30/2024$ 333K$ -62.52M$ -62.19M
3/31/2024$ 325K$ -122.05M$ -121.72M
12/31/2023$ 530K$ -118.95M$ -118.42M
9/30/2023$ 566K$ -116M$ -115.44M
6/30/2023$ 668K$ -117.75M$ -117.08M
3/31/2023$ 734K$ -133.66M$ -132.92M
Previous (option currently disabled)
1 (current)
Next (option currently disabled)

Key Performance Insights, Last 5 Years

  • KARYOPHARM THERAPEUTICS INC's latest trailing twelve months (TTM) EBITDA stands at $ -173.76M.
  • Over the past 5 years, KARYOPHARM THERAPEUTICS INC's average EBITDA has been $ -109.3M.
  • The median EBITDA for KARYOPHARM THERAPEUTICS INC during this period was $ -116.26M
  • KARYOPHARM THERAPEUTICS INC reached its highest EBITDA over the past 5 years at $ -19.64M.
  • The lowest EBITDA recorded by KARYOPHARM THERAPEUTICS INC in the same timeframe $ -182.6M

KARYOPHARM THERAPEUTICS INC's EBITDA vs. competitors

We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue

EBITDA Benchmarks
CompanyEBITDA
IPSC : CENTURY THERAPEUTICS INC $ -7.37MMRSN : MERSANA THERAPEUTICS INC $ -65.59MADAP : ADAPTIMMUNE THERAPEUTICS PLC $ -149.75MIGC : IGC PHARMA INC $ -5.75MXLO : XILIO THERAPEUTICS INC $ -54.59MALXO : ALX ONCOLOGY HOLDINGS INC $ -114.05MGBIO : GENERATION BIO CO $ -67.79MCLSD : CLEARSIDE BIOMEDICAL INC $ -26.67MTAOX : TAO SYNERGIES INC $ -28.41MESLA : ESTRELLA IMMUNOPHARMA INC $ -12.08M

Similar metrics to EBITDA:

Definition of Earnings Before Interest Taxes & Depreciation Amortization (EBITDA)

[Calculation] EBITDA is a non-GAAP accounting metric that lets investors asses profitability net of expenses dependent on financing decision, tax strategy and depreciation schedules. It is calculated by adding depreciation and amortisation expenses [DepAmor] back to [EBIT].
EBIT + DepAmor
(=) EBITDA EBITDA for KARYOPHARM THERAPEUTICS INC is calculated as follows: EBIT [ $ -174.72M ] + DepAmor [ $ 959K ]
(=) EBITDA [ $ -173.76M ]

KPTI - Earnings Before Interest Taxes & Depreciation Amortization (EBITDA), Last 5 years

$ -182.6M

Minimum

Jun 30, 2021

$ -19.64M

Maximum

Mar 31, 2025

$ -109.3M

Average

$ -116.26M

Median

EBITDA Benchmark Analysis

 The chart above depicts the distribution of EBITDA for companies in the Total Stock Market. The average EBITDA of the companies is $ 58.79M with a standard deviation of $ 166.94M.
The following table provides additional summary stats:
EBITDA in the Market:
filtered constituents3.25K
min$ -493.3M
max$ 590.6M
average$ 58.79M
median$ 8.83M
std$ 166.94M